TrumpRx and Most-Favored-Nation Pricing: What Changed for GLP-1s

A most-favored-nation idea is simple to state. The goal is to bring a branded drug's price in the United States in line with the lower prices paid in comparably developed countries ². TrumpRx is the government website attached to that effort for several medicines, GLP-1s among them ³.

TrumpRx links to direct-to-consumer discounts for people not using their health insurance ¹. In practice, that means a direct, cash-style price for a branded product. It is not insurance, and it is not a coupon stacked on top of a plan. It is a manufacturer or program list price for people who buy that way. Whether you pay that exact figure depends on the product, the dose, and the channel you use.

Here are the TrumpRx figures NPR reported on May 6, 2026 ¹. Read them as manufacturer or program prices for specific branded products, not as a single price anyone is guaranteed.

The reported ranges:

• Wegovy® injectables: $199 to $399
• Oral Wegovy: up to $299
• Foundayo™ (oral): up to $349
• Zepbound® KwikPen: up to $699

A few things worth noticing. The ranges are wide, because a starting product and a higher-dose product are not priced the same. Oral and injectable versions are listed separately. And a single headline number, like "$199," is the floor of a range, not the price for every option.

These figures are manufacturer or program prices reported in the press. They are illustrative of the 2026 landscape. They are not a quote of any telehealth provider's prices, and a provider does not set manufacturer pricing. Any price you pay for treatment should be disclosed in full before checkout, with the recurring monthly charge until canceled, and a way to cancel anytime in your account, no phone call required.

This arrangement changes one thing clearly: some branded GLP-1s have a published direct price that is lower than their earlier list price ³. That is real, and it is dated ¹.

It does not change several other things. It does not, by itself, change whether your insurance may cover a GLP-1, and it does not set what a pharmacy or a telehealth provider charges for the care around the medication. It also sits next to other 2026 access changes, like the Medicare GLP-1 Bridge copay program that starts July 1, 2026, which follow their own rules and dates ⁴. A lower manufacturer price is one piece of the total cost, not the whole bill.

It also does not touch the compounding question. A patient-specific compounded GLP-1 is a different thing from a branded product. It is a preparation made by a state-licensed 503A pharmacy under a prescription written for one person. It is not a generic of the brand, and it is not equivalent to the branded product, so a branded price list does not describe it.

The honest standard for any GLP-1 price, a manufacturer figure or a provider's, is the all-in number. A published list price is only useful next to the rest of the math.

A good provider shows you four things before your card is charged: the full monthly cost, how that cost changes as your dose changes, the recurring charge, and how to cancel. If a price is quoted without those four, it is a headline, not a bill. (This four-part standard is the one sipra was built around.)

So when you see a TrumpRx figure, treat it as a starting data point for a branded product on a given date. Then ask what the complete cost looks like for your situation, decided with a licensed clinician who knows your history.

Some branded GLP-1 prices got lower and got published in 2026, and that is a dated fact worth knowing. The figures are manufacturer or program prices for specific products, not a single guaranteed price and not a quote of what any one provider charges.

Your next step is simple. If a GLP-1 price catches your eye, ask one question: what is the full, all-in monthly cost, and how do I cancel? A clear answer is the sign of a provider worth your time.